Delving into the Latest Updates on Biotle Biotechnology (Hangzhou) Co., Ltd. with Synapse

Overview

Tags

Immune System Diseases

Endocrinology and Metabolic Disease

Trispecific T-cell engager (TriTE)

Antibody

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	4
Neoplasms	2
Endocrinology and Metabolic Disease	2
Nervous System Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Unknown	2
Antibody	2
Trispecific T-cell engager (TriTE)	1
Bispecific antibody	1

Top 5 Target	Count

FcRn(IgG receptor FcRn large subunit p51)	1
BCMA x CD3 x GPRC5D	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Preclinical

Phase 1

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

BTL-203 ( FcRn )	Myasthenia Gravis More	IND Approval
BTL-101 ( BCMA x CD3 x GPRC5D )	Autoimmune Diseases More	Preclinical
BTL-306	Metabolic Diseases More	Preclinical
BTL-410	Autoimmune Diseases More	Preclinical
BTL-316	Metabolic Diseases More	Discovery